Rare Cancer News & Clinical Trials » Trial

Trial - Neuroendocrine Cancers (43 unread)

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Posted: January 20th, 2023, 3:00pm GMT

Conditions: Metastatic Malignant Neoplasm in the Viscera; Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation; Metastatic Prostate Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8
Intervention: Drug: Lutetium Lu 177 Dotatate
Sponsor: National Cancer Institute (NCI)
Not yet recruiting
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Posted: January 18th, 2023, 3:00pm GMT

Conditions: Metastatic Pancreatic Neuroendocrine Tumor; Pancreatic Neoplasm; Stage III Pancreatic Neuroendocrine Tumor AJCC v8; Stage IV Pancreatic Neuroendocrine Tumor AJCC v8; Unresectable Pancreatic Neuroendocrine Tumor
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Sunitinib Malate
Sponsor: National Cancer Institute (NCI)
Not yet recruiting
Radiographic Prediction of the Nerve Origin of Neck Peripheral Nerve Sheath Tumors

Posted: January 13th, 2023, 3:00pm GMT

Conditions: Peripheral Nerve Sheath Tumors; Schwannoma of Neck
Intervention: Procedure: Excision
Sponsor: National Cheng-Kung University Hospital
Recruiting
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Posted: January 11th, 2023, 3:00pm GMT

Conditions: Small Cell Lung Cancer Extensive Stage; Large Cell Neuroendocrine Carcinoma of the Lung
Intervention: Biological: LB2102
Sponsor: Legend Biotech USA Inc
Not yet recruiting
Dual-Tracer Theranostic PET

Posted: January 11th, 2023, 3:00pm GMT

Conditions: Neuroendocrine Tumors; Prostate Cancer
Interventions: Diagnostic Test: Single-Tracer FDG PET/CT Exam; Diagnostic Test: Single-Tracer Cu64-DOTATATE PET/CT Exam; Diagnostic Test: Single-Tracer Ga68-DOTATATE PET/CT Exam; Diagnostic Test: Single-Tracer PSMA PET/CT Exam
Sponsors: University of Utah; MultiFunctional Imaging LLC; National Cancer Institute (NCI)
Recruiting
A Study of TY-1091 in Patients With Advanced Solid Tumors

Posted: January 9th, 2023, 3:00pm GMT

Conditions: RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer; Neoplasms
Intervention: Drug: TY-1091
Sponsor: TYK Medicines, Inc
Not yet recruiting
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors

Posted: January 5th, 2023, 3:00pm GMT

Condition: Neuroendocrine Tumors (NET)
Intervention: Diagnostic Test: 68Ga-HA-DOTATATE PET/CT imaging
Sponsor: Alberta Health services
Recruiting
Surgery With Extended (D3) Mesenterectomy for Small Bowel Tumors

Posted: January 4th, 2023, 3:00pm GMT

Conditions: Small Bowel Cancer; Small Bowel Carcinoid Tumor; Quality of Life; Lymph Node Metastases; Tumor Metastasis
Intervention: Procedure: Surgery with extended (D3) mesenterectomy for small bowel tumors
Sponsors: Sykehuset i Vestfold HF; Helse Sor-Ost; University of Geneva, Switzerland; Oslo University Hospital; CarciNor
Recruiting
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors

Posted: December 30th, 2022, 3:00pm GMT

Conditions: Solid Tumors; Melanoma; NSCLC; CRC; ATC
Interventions: Drug: CFT1946; Drug: Trametinib
Sponsor: C4 Therapeutics, Inc.
Recruiting
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma

Posted: December 23rd, 2022, 3:00pm GMT

Conditions: Malignant Melanoma; Liver Metastases
Intervention: Drug: Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel
Sponsors: Fujian Cancer Hospital; Jiangsu Hengrui Pharmaceutical Co., Ltd.; SunWay Biotech Co., LTD.
Not yet recruiting
$Permalink for 'A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3'$
A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3

Posted: December 15th, 2022, 3:00pm GMT

Conditions: Small Cell Lung Cancer (SCLC); Large Cell Neuroendocrine Cancer (LCNEC); Neuroendocrine Prostate Cancer (NEPC); Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Intervention: Drug: PT217
Sponsor: Phanes Therapeutics
Not yet recruiting
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Asymptomatic Melanoma Brain Metastases

Posted: December 7th, 2022, 3:00pm GMT

Condition: Metastatic Melanoma
Intervention: Biological: Lifileucel (LN-144)
Sponsors: Memorial Sloan Kettering Cancer Center; Iovance Biotherapeutics, Inc.
Recruiting
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Posted: November 17th, 2022, 3:00pm GMT

Conditions: Small Cell Lung Cancer; Neuroendocrine Carcinoma
Interventions: Drug: RO7616789; Drug: Tocilizumab
Sponsor: Hoffmann-La Roche
Recruiting
A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Posted: October 7th, 2022, 2:00pm GMT

Conditions: Cutaneous Melanoma; Non-small Cell Lung Cancer; Colorectal Neoplasms; Pancreatic Neoplasms; Mesothelioma
Intervention: Drug: SGN-BB228
Sponsor: Seagen Inc.
Recruiting
A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery

Posted: July 14th, 2022, 2:00pm GMT

Conditions: Sentinel Lymph Node Biopsy; Breast Cancer; Melanoma
Intervention: Drug: pudexacianinium chloride
Sponsor: Astellas Pharma Inc
Recruiting
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

Posted: December 27th, 2021, 3:00pm GMT

Conditions: Solid Tumor; Breast Tumor; Colon Tumor, Malignant; Lung Tumor; Urologic Cancer; Pancreatic Cancer; Melanoma; Metastatic Cancer; Locally Advanced Solid Tumor; Esophageal Cancer; Endometrial Cancer; Head and Neck Cancer
Intervention: Drug: Niraparib
Sponsors: Tempus Labs; GlaxoSmithKline
Recruiting
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Posted: September 10th, 2021, 2:00pm GMT

Conditions: Metastatic Malignant Neoplasm in the Liver; Pancreatic Neuroendocrine Tumor; Stage I Pancreatic Neuroendocrine Tumor AJCC v8; Stage II Pancreatic Neuroendocrine Tumor AJCC v8; Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Interventions: Drug: Capecitabine; Drug: Temozolomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Posted: August 11th, 2021, 2:00pm GMT

Conditions: Bile Duct Cancer; Gall Bladder Cancer; Breast Cancer; Neuroendocrine Tumors; Ovarian Cancer; Pancreatic Adenocarcinoma; Soft Tissue Sarcoma; Vulvar Cancer; Prostate Cancer
Interventions: Drug: Atezolizumab; Drug: Tivozanib
Sponsors: University of Florida; Genentech, Inc.; Aveo Oncology Pharmaceuticals
Recruiting
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

Posted: June 11th, 2021, 2:00pm GMT

Conditions: Urothelial Cancer; Bladder Cancer; Genitourinary Cancer; Urogenital Neoplasms; Urogenital Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Posted: April 19th, 2021, 2:00pm GMT

Conditions: Prostate Cancer Metastatic; Neuroendocrine Tumors
Interventions: Drug: Pembrolizumab; Drug: Lenvatinib
Sponsors: Ulka Vaishampayan; Merck Sharp & Dohme LLC; University of Michigan
Recruiting
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Posted: April 1st, 2021, 2:00pm GMT

Conditions: HRD Cancer; SCLC; Advanced Solid Tumors
Interventions: Drug: Berzosertib; Drug: Sacituzumab Govitecan
Sponsor: National Cancer Institute (NCI)
Recruiting
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Posted: March 17th, 2021, 2:00pm GMT

Conditions: SCLC; Small Cell Cancer; Advanced Solid Tumor; High Grade Neuroendocrine Cancers
Interventions: Drug: Lurbinectedin; Drug: Berzosertib
Sponsor: National Cancer Institute (NCI)
Recruiting
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Posted: February 18th, 2021, 3:00pm GMT

Conditions: Malignant Thyroid Gland Neoplasm; Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Thyroid Gland Anaplastic Carcinoma; Thyroid Gland Medullary Carcinoma; Thyroid Gland Papillary Carcinoma; Thyroid Gland Squamous Cell Carcinoma
Interventions: Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Selpercatinib; Procedure: Therapeutic Conventional Surgery
Sponsor: M.D. Anderson Cancer Center
Recruiting
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Posted: December 14th, 2020, 3:00pm GMT

Conditions: Advanced Lung Carcinoid Tumor; Functioning Lung Carcinoid Tumor; Locally Advanced Lung Neuroendocrine Neoplasm; Lung Atypical Carcinoid Tumor; Lung Neuroendocrine Neoplasm; Lung Typical Carcinoid Tumor; Metastatic Lung Carcinoid Tumor; Metastatic Lung Neuroendocrine Neoplasm; Non-Functioning Lung Carcinoid Tumor; Recurrent Lung Neuroendocrine Neoplasm; Unresectable Lung Carcinoid Tumor; Unresectable Lung Neuroendocrine Neoplasm
Interventions: Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate
Sponsor: National Cancer Institute (NCI)
Recruiting
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

Posted: September 10th, 2020, 2:00pm GMT

Conditions: Neuroendocrine Tumors; Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
Intervention: Drug: 177Lu-DOTATATE
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Posted: September 4th, 2020, 2:00pm GMT

Conditions: EGFR-Mutated Non-Small-Cell Lung Carcinoma; Small Cell/Neuroendocrine
Interventions: Drug: Olaparib; Drug: Durvalumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

Posted: August 10th, 2020, 2:00pm GMT

Conditions: Appendix Carcinoma; Colon Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Malignant Digestive System Neoplasm; Pancreatic Carcinoma; Rectal Carcinoma; Small Intestinal Carcinoma; Anal Carcinoma; Digestive System Carcinoma; Digestive System Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor
Interventions: Procedure: Acupuncture Therapy; Procedure: Acupressure Therapy; Procedure: Oral Cryotherapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment
Sponsors: University of Washington; National Cancer Institute (NCI); The Safeway Foundation
Recruiting
Neuroendocrine and Adrenal Tumors

Posted: June 16th, 2020, 2:00pm GMT

Conditions: Neuroendocrine Tumors; Adrenal Tumor
Intervention: Other: No intervention
Sponsor: University of Pennsylvania
Not yet recruiting
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

Posted: May 20th, 2020, 2:00pm GMT

Conditions: Advanced Adrenal Gland Pheochromocytoma; Advanced Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Paraganglioma; Unresectable Adrenal Gland Pheochromocytoma; Unresectable Paraganglioma
Interventions: Drug: Olaparib; Other: Quality-of-Life Assessment; Drug: Temozolomide
Sponsor: National Cancer Institute (NCI)
Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Posted: December 13th, 2019, 3:00pm GMT

Conditions: Solid Tumor; Non-Small Cell Lung Cancer; Melanoma; Head and Neck Cancer; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma
Interventions: Drug: INBRX-106 - Hexavalent OX40 agonist antibody; Drug: Pembrolizumab
Sponsors: Inhibrx, Inc.; Merck Sharp & Dohme LLC
Recruiting
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

Posted: September 26th, 2019, 2:00pm GMT

Conditions: Thyroid Cancer; Prostate Cancer; Neuroendocrine Tumors
Interventions: Other: Biological collection; Other: tumor collection
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Recruiting
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Posted: September 11th, 2019, 2:00pm GMT

Conditions: Gastroenteropancreatico Tumors; Neuroendocrine Tumors; Neuroendocrine Neoplasms
Interventions: Drug: Lu-177-DOTATATE; Drug: Olaparib; Diagnostic Test: Ga dotatate scanning; Diagnostic Test: FDG-PET scanning; Drug: Amino Acid infusion
Sponsor: National Cancer Institute (NCI)
Recruiting
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Posted: August 29th, 2019, 2:00pm GMT

Conditions: VHL Pancreatic Neuroendocrine Tumors; Von Hippel-Lindau Disease; Neuroendocrine Tumors
Intervention: Drug: 68-Gallium DOTATATE
Sponsor: National Cancer Institute (NCI)
Recruiting
$Permalink for 'Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors'$
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Posted: March 27th, 2019, 2:00pm GMT

Conditions: Advanced Digestive System Neuroendocrine Neoplasm; Digestive System Neuroendocrine Tumor; Foregut Neuroendocrine Tumor; Hindgut Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Neoplasm; Midgut Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Refractory Digestive System Neuroendocrine Neoplasm
Intervention: Drug: Abemaciclib
Sponsors: University of Washington; Eli Lilly and Company
Recruiting
Study of INBRX-105 in Patients With Solid Tumors

Posted: January 18th, 2019, 3:00pm GMT

Conditions: Metastatic Solid Tumors; Non-small Cell Lung Cancer; Melanoma; Head and Neck Squamous Cell Carcinoma; Gastric Adenocarcinoma; Renal Cell Carcinoma; Urothelial Carcinoma; Esophageal Adenocarcinoma
Interventions: Drug: INBRX-105 - PDL1x41BB antibody; Drug: Pembrolizumab
Sponsor: Inhibrx, Inc.
Recruiting
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Posted: July 16th, 2018, 2:00pm GMT

Conditions: Metastatic Kidney Medullary Carcinoma; Metastatic Renal Cell Carcinoma; SMARCB1 Negative; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
Interventions: Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Drug: Ixazomib; Drug: Ixazomib Citrate
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Inhibition of CArbonic Anhydrase in Combination With Platinum and Etoposide-based Radiochemotherapy in Patients With Localized Small Cell Lung Cancer

Posted: March 16th, 2018, 2:00pm GMT

Condition: Small Cell Lung Cancer
Intervention: Drug: acetazolamide in combination with platinum and etoposide-based radiochemotherapy
Sponsor: Centre Antoine Lacassagne
Recruiting
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Posted: July 2nd, 2017, 2:00pm GMT

Conditions: Pheochromocytoma; Paraganglioma; Neuroendocrine Tumors; Neuroendocrine Neoplasms
Interventions: Drug: Lu-177-DOTATATE; Drug: Ga-68-DOTATATE; Drug: F-18-FDG; Drug: Amino Acid solution
Sponsor: National Cancer Institute (NCI)
Recruiting
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

Posted: May 9th, 2017, 2:00pm GMT

Condition: Neuroendocrine Tumors
Intervention: Drug: [68]Ga-HA-DOTATATE
Sponsor: AHS Cancer Control Alberta
Recruiting
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Posted: December 11th, 2015, 3:00pm GMT

Conditions: Advanced Cancer; Anal Carcinoma; Anal Cancer; Biliary Cancer; Cholangiocarcinoma; Bile Duct Cancer; Neuroendocrine Tumor; Carcinoid Tumor; Endometrial Carcinoma; Endometrial Cancer; Cervical Carcinoma; Cervical Cancer; Vulvar Carcinoma; Vulvar Cancer; Small Cell Lung Carcinoma; Small Cell Lung Cancer (SCLC); Mesothelioma; Thyroid Carcinoma; Thyroid Cancer; Salivary Gland Carcinoma; Salivary Gland Cancer; Salivary Cancer; Parotid Gland Cancer; Advanced Solid Tumors; Colorectal Carcinoma
Intervention: Biological: pembrolizumab
Sponsor: Merck Sharp & Dohme LLC
Recruiting
A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Posted: December 3rd, 2015, 3:00pm GMT

Condition: Melanoma
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Aldesleukin; Drug: Pembrolizumab; Biological: young TIL
Sponsor: National Cancer Institute (NCI)
Recruiting
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Posted: October 7th, 2013, 2:00pm GMT

Conditions: Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Biological: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine Phosphate; Other: Laboratory Biomarker Analysis; Biological: NGFR-transduced Autologous T Lymphocytes; Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

Posted: June 13th, 2013, 2:00pm GMT

Condition: Carcinoma, Neuroendocrine
Intervention: Drug: [177]Lu-DOTA-TATE
Sponsor: AHS Cancer Control Alberta
Recruiting

← Trial - Merkel Cell Cancer Google - Gall Bladder Cancer →

Rare Cancer News & Clinical Trials » Trial - Neuroendocrine Cancers

Feeds

Trial - Neuroendocrine Cancers (43 unread)

Posted: January 20th, 2023, 3:00pm GMT

Posted: January 18th, 2023, 3:00pm GMT

Posted: January 13th, 2023, 3:00pm GMT

Posted: January 11th, 2023, 3:00pm GMT

Posted: January 11th, 2023, 3:00pm GMT

Posted: January 9th, 2023, 3:00pm GMT

Posted: January 5th, 2023, 3:00pm GMT

Posted: January 4th, 2023, 3:00pm GMT

Posted: December 30th, 2022, 3:00pm GMT

Posted: December 23rd, 2022, 3:00pm GMT

Posted: December 15th, 2022, 3:00pm GMT

Posted: December 7th, 2022, 3:00pm GMT

Posted: November 17th, 2022, 3:00pm GMT

Posted: October 7th, 2022, 2:00pm GMT

Posted: July 14th, 2022, 2:00pm GMT

Posted: December 27th, 2021, 3:00pm GMT

Posted: September 10th, 2021, 2:00pm GMT

Posted: August 11th, 2021, 2:00pm GMT

Posted: June 11th, 2021, 2:00pm GMT

Posted: April 19th, 2021, 2:00pm GMT

Posted: April 1st, 2021, 2:00pm GMT

Posted: March 17th, 2021, 2:00pm GMT

Posted: February 18th, 2021, 3:00pm GMT

Posted: December 14th, 2020, 3:00pm GMT

Posted: September 10th, 2020, 2:00pm GMT

Posted: September 4th, 2020, 2:00pm GMT

Posted: August 10th, 2020, 2:00pm GMT

Posted: June 16th, 2020, 2:00pm GMT

Posted: May 20th, 2020, 2:00pm GMT

Posted: December 13th, 2019, 3:00pm GMT

Posted: September 26th, 2019, 2:00pm GMT

Posted: September 11th, 2019, 2:00pm GMT

Posted: August 29th, 2019, 2:00pm GMT

Posted: March 27th, 2019, 2:00pm GMT

Posted: January 18th, 2019, 3:00pm GMT

Posted: July 16th, 2018, 2:00pm GMT

Posted: March 16th, 2018, 2:00pm GMT

Posted: July 2nd, 2017, 2:00pm GMT

Posted: May 9th, 2017, 2:00pm GMT

Posted: December 11th, 2015, 3:00pm GMT

Posted: December 3rd, 2015, 3:00pm GMT

Posted: October 7th, 2013, 2:00pm GMT

Posted: June 13th, 2013, 2:00pm GMT